

CLAIMS

1. A method of treatment of a patient suffering from or susceptible to a condition in which an increase in the amount of tyrosine hydroxylase (TH) with the central nervous system (CNS) of said patient is desirable, which method comprises the step of increasing the effective amount of GPE or an analog thereof within the CNS of said patient.
2. A method of effecting an increase in the amount of tyrosine hydroxylase (TH) within the CNS of a patient for therapy or prophylaxis of a neurological disorder or condition involving dopaminergic neurons, said method comprising the step of increasing the effective amount of GPE or an analog thereof within the CNS of said patient.
3. A method of treatment of a patient suffering from or susceptible to a condition in which an increase of tyrosine hydroxylase (TH)-mediated dopamine production is desirable, which method comprises the step of increasing the effective amount of GPE or an analog thereof within the CNS of said patient.
4. A method of treatment as claimed in claim 1, claim 2 or claim 3 wherein the concentration of GPE or an analog thereof is increased by administering to said patient an effective amount of GPE or said analog of GPE or of a pro-drug thereof.
5. A method of treatment as claimed in claim 1, claim 2 or claim 3 wherein the concentration of GPE is increased in the CNS by direct administration of GPE.
6. A method as claimed in any one of claims 1 to 5 which is prophylactic.
7. A method as claimed in any one of claims 1 to 5 which is therapeutic.
8. A method of treatment or prophylaxis of Parkinson's disease in a patient, which method comprises increasing tyrosine hydroxylase (TH)-mediated

dopamine production by dopaminergic neurons within the substantia nigra of the CNS by the step of increasing the effective amount of GPE or an analog thereof within the CNS of said patient.

- 5 9. The use of GPE or an analog thereof in the preparation of a medicament for use in increasing the amount of tyrosine hydroxylase (TH) within the CNS of a patient for therapeutic or prophylactic purposes.
- 10 10. The use of GPE or an analog thereof in the preparation of a medicament for use in the treatment of Parkinson's disease mediated by increasing expression of tyrosine hydroxylase (TH).
- 15 11. The use of GPE or an analog thereof in the preparation of a medicament for use in increasing tyrosine hydroxylase (TH)-mediated dopamine production within the CNS of a patient.
- 20 12. The use of GPE or an analog thereof in the preparation of a medicament for use in increasing tyrosine hydroxylase (TH)-mediated dopamine production by dopaminergic neurons in the substantia nigra of the CNS in order to treat Parkinson's disease.